Wednesday, May 8, 2013


The FDA has approved the use of Kcentra for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding.

Unlike plasma, Kcentra can be administered rapidly because it does not require thawing, though Kcentra is made from the pooled plasma of healthy donors and is processed to minimize risk for transmitting viral and other diseases, according to the FDA press release. Kcentra (CSL Behring) is used in conjunction with the administration of vitamin K.

Study has demonstrated that Kcentra was similar to plasma in terms of stopping acute major bleeding.

Another advantage is, Kcentra is administered in a significantly lower volume than plasma at recommended doses, providing an alternative for those patients who may not tolerate the volume of plasma.

As expected, Kcentra is associated with some risk of arterial and venous thromboembolic complications.

See full prescribing info here

No comments:

Post a Comment